Changes in cytokine levels of patients with ovarian endometriosis after treatment with gonadotropin-releasing hormone analogue, ultrasound-guided drainage, and intracystic recombinant interleukin-2

What Was Tested

The paper reports a study of Triptorelin in the context of endometriosis, published as a randomized controlled trial.

To determine the changes in cytokine levels from women with endometriomas who are treated with recombinant interleukin-2 after ultrasound-guided cyst aspiration, and to relate these changes to the clinical results observed in these patients.

Who Took Part

PubMed indexes the participants as adults, women only.

Twenty-four women with endometriosis-related symptoms and endometriomas.

Endometriomas in women receiving GnRH analogues and undergoing transvaginal ultrasound-guided cyst aspiration were injected with dextrose that did or did not contain recombinant interleukin-2 (IL-2).

How the Study Was Run

The design is described as randomized and double-blind.

Because people in this Triptorelin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the participants and researchers unaware of who received Triptorelin.

A double-blind randomized controlled trial.

Serum samples were collected before and after treatment.

What Was Measured

The subject headings attached to it are Antineoplastic Agents, Antineoplastic Agents, Hormonal, Cytokines, Drainage, Endometritis, Immunologic Factors and Injections, Intralesional.

What This Means in Plain Language

The paper is a randomized and double-blind study of Triptorelin in people with endometriosis.

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2005 (Fertility and sterility), a journal based in United States.

More context: the Triptorelin compound page, Endometriosis research.